Assertio Therapeutics Inc. (DepoMed Inc.) (ASRT)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 SOUTH SAUNDERS RD LAKE FOREST, IL 60045

DepoMed is a pharmaceutical company focused on neurology, pain and other diseases of the central nervous system. Gralise (gabapentin) is Co.'s formulation of gabapentin for the management of postherpetic neuralgia. Co. also provides Glumetza (metformin hydrochloride extended release tablets), a treatment for adults with type two diabetes. In addition, Co. has two product candidates in clinical development, DM-1992 for Parkinson's disease and Serada for menopausal hot flashes. Additionally, Co. has a number of other license and development arrangements associated with its Acuform gastroretentive drug delivery technology.

Data as of 2020-08-01
Market Cap94.928 Million Shares Outstanding105.405 Million Avg 30-day Volume1.263 Million
P/E Ratio Dividend Yield EPS-2.29
Price/Sales0.702 Price cash flow ratio1.8 Price free cash flow ratio0.2
Book Value0.8 Price to Tangible Book1.68 Alpha-0.22
Short Interest Ratio % Short Interest to Float R-squared1.0
BETA4.9638 52-week High/Low1.15 / 0.77 Stddev0.12886
View SEC Filings from ASRT instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 93 36 (2.36%)
Aggregate 13F shares on 03/31/2020: 53.145 Million 40.076 Million
Aggregate 13F shares on 12/31/2019: 66.009 Million 45.321 Million
Percent change: -19.49% -11.57%
Funds creating new positions: 9 3
Funds Adding to an existing position: 23 9
Funds closing out their position: 26 9
Funds reducing their position: 37 13
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ASRT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ASRT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WALBERT TIMOTHY P CHAIRMAN, PRESIDENT AND CEO

  • Officer
  • Director
743,991 2020-08-06 2

HIGGINS ARTHUR J

  • Director
19,814 2020-06-30 7

DAWES KAREN A

  • Director
100,734 2020-06-18 1

MCKEE WILLIAM

  • Director
0 2020-06-17 1

SCHOENECK JAMES A

  • Director
68,822 2020-06-04 0

DONENBERG PHILLIP B.

  • Director
0 2020-06-04 0

TYREE JAMES L

  • Director
13,069 2020-05-21 1

TIMMINS MEGAN C. SVP, GEN CSL & SEC

  • Officer
0 2020-05-20 2

STROBECK MARK CHIEF OPERATING OFFICER

  • Officer
0 2020-05-20 2

SMITH TODD N PRESIDENT AND CEO

  • Officer
  • Director
0 2020-05-20 2

SMILEY ANDREA HESLIN

  • Director
0 2020-05-20 2

CR GROUP L.P.

CRG PARTNERS III - PARALLEL FUND B (CAYMAN) L.P.

CRG PARTNERS III - PARALLEL FUND (A) L.P.

CRG PARTNERS III (CAYMAN) LEV AIV I L.P.

CRG PARTNERS III (CAYMAN) UNLEV AIV I L.P.

CRG PARTNERS III L.P.

LOAN SECURITY HOLDINGS I LLC

  • 10% Owner
0 2020-05-20 1

STAPLE PETER D

  • Director
445,380 2020-05-19 2

LAVIGNE LOUIS J JR

  • Director
0 2020-05-19 0

PEISERT DANIEL A. EVP AND CFO

  • Officer
0 2020-05-19 10

MASON HEATHER L

  • Director
251,894 2020-05-19 2

WHEADON DAVID E.

  • Director
237,500 2020-05-19 3

ANIDO VICENTE JR CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
225,550 2020-05-16 0

FOGARTY JAMES P

  • Director
17,629 2020-04-23 0

BUKOFZER STAN SVP, CHF SCITFC & TECH OFFICER

  • Officer
62,916 2020-04-02 5

SAVAGE ROBERT G.

0 2020-04-01 0

GALEOTA JAMES JR

  • Director
12,492 2020-03-30 1

SMITH CRAIG R

  • Director
54,469 2020-03-13 0

SAKS SAMUEL R CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-28 0

TANG KEVIN C

TANG CAPITAL PARTNERS LP

TANG CAPITAL MANAGEMENT LLC

  • Director
  • 10% Owner
8,080,345 2020-01-30 0

MOLINELLI GAVIN

  • Director
No longer subject to file 2018-12-07 0

GOSLING MATTHEW M SVP, GENERAL COUNSEL

  • Officer
0 2018-05-11 0

MORETTI AUGUST J CHIEF FINANCIAL OFFICER & SVP

  • Officer
74,447 2018-03-31 0

VETTICADEN SANTOSH SVP, CHIEF MEDICAL OFFICER ***

  • Officer
0 2018-02-06 0

VARGAS THADD M SVP, BUSINESS DEVELOPMENT

  • Officer
0 2017-06-13 0

SRINIVAS G. RAO SVP AND CHIEF MEDICAL OFFICER

  • Officer
19,527 2017-04-02 0

ZENOFF DAVID B

  • Director
93,999 2017-02-21 0

STERN JULIAN N

  • Director
0 2016-06-08 0

SHIVELY RICHARD SCOTT SVP & CHIEF COMMERCIAL OFFICER

  • Officer
4,290 2016-04-02 0

BURRILL STEVEN

  • Director
0 2013-12-10 0

SWEENEY MICHAEL MD CMO AND VP, R&D

  • Officer
9,084 2013-12-02 0

CAMERON TAMMY VP, FINANCE

  • Officer
0 2011-09-01 0

PELZEL CARL A PRESIDENT AND CEO

  • Officer
  • Director
0 2011-01-14 0

SHELL JOHN N VP, OPERATIONS

  • Officer
0 2008-01-25 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments